Global Human Microbiome Market Report and Forecast 2023-2031

Global Human Microbiome Market Report and Forecast 2023-2031


Global Human Microbiome Market Outlook:

The global human microbiome market size was valued at USD 476.7 million in 2022, driven by the increasing the rising technical advancements in diagnostic tools across the globe. The market size is anticipated to grow at a CAGR of 22.4% during the forecast period of 2023-2031 to achieve a value of USD 2968.1 million by 2031.

Human Microbiome: Introduction

The human microbiome refers to the collection of microorganisms, including bacteria, viruses, fungi, and other microbes, that reside within and on the human body. These microorganisms play a crucial role in maintaining human health by contributing to various physiological processes, such as digestion, immune function, and metabolism. The study of the human microbiome has gained significant attention in recent years due to its potential implications for understanding and treating a wide range of diseases and conditions.

Key Trends in the Human Microbiome Market

Some key trends involved in the human microbiome market are as follows:
  • Microbiome-based therapies: There is growing interest in developing microbiome-based therapies, such as probiotics, prebiotics, and fecal microbiota transplantation (FMT). These approaches aim to manipulate the composition and function of the microbiome to improve health outcomes and treat various diseases.
  • Personalized medicine: The understanding of individual variations in the human microbiome has led to the emergence of personalized medicine approaches. By analyzing an individual's microbiome profile, healthcare providers can tailor treatment strategies and interventions to optimize health outcomes.
  • Diagnostic tools and techniques: Advances in sequencing technologies and bioinformatics have revolutionized the field of microbiome research, enabling the development of new diagnostic tools and techniques. These include metagenomic sequencing, microbial gene expression analysis, and computational modeling, which provide insights into the composition and function of the human microbiome.
  • Microbiome and disease associations: Researchers are uncovering associations between the human microbiome and various diseases, including gastrointestinal disorders, autoimmune diseases, obesity, and mental health conditions. Understanding these associations may lead to the development of novel diagnostic markers and therapeutic interventions.
Human Microbiome Market Segmentations

Market Breakup by Product Type
  • Probiotics
  • Prebiotics
  • Medical Foods
  • Supplements
  • Others
Market Breakup by Application
  • Therapeutics
  • Diagnostics
Market Breakup by Disease Type
  • Obesity
  • Diabetes
  • Autoimmune Disorder
  • Metabolic and Gastrointestinal Disorders
  • Cancer
  • Other Disease
Market Breakup by Distribution Channel
  • Retail Pharmacies
  • Online Pharmacies
  • Supermarkets and Hypermarkets
  • Others
Market Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Human Microbiome Market Scenario

The market for human microbiome products and services is experiencing significant growth as researchers and healthcare providers recognize the importance of the microbiome in human health. The human microbiome market encompasses various sectors, including therapeutics, diagnostics, and personalized medicine.

The demand for microbiome-based therapeutics is increasing as researchers discover the potential of manipulating the microbiome to treat and prevent diseases. Probiotics, prebiotics, and fecal microbiota transplantation (FMT) are among the microbiome-based therapies gaining traction in the market. These therapies aim to restore or modify the composition of the microbiome to promote health and address specific conditions.

In the field of diagnostics, there is a growing need for tools and technologies that can analyze and interpret the human microbiome. Metagenomic sequencing, microbial gene expression analysis, and other advanced techniques are being developed to identify and quantify specific microbial species and functional pathways in the microbiome. These diagnostic approaches have the potential to improve disease detection, monitoring, and treatment selection.

Personalized medicine is another area of focus within the human microbiome market. With advancements in sequencing technologies and data analytics, healthcare providers can analyze an individual's microbiome profile and tailor treatment strategies accordingly. This personalized approach holds promise for optimizing therapeutic outcomes and minimizing adverse effects.

The integration of microbiome research into healthcare is driving market growth. Pharmaceutical companies, biotechnology firms, and research institutions are investing in the development of microbiome-focused products and services. The market is characterized by collaborations between industry players, academic institutions, and healthcare providers to further understand the role of the microbiome and translate research findings into clinically applicable solutions.

Human Microbiome Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • ENTEROME
  • Yakult
  • DuPont
  • Metabiomics Corporation
  • ViThera Pharmaceuticals, Inc.
  • Second Genome Inc.
  • MICROBIOME THERAPEUTICS LLC
  • Vedanta Biosciences, Inc.
  • Osel, Inc.
  • Seres Therapeutics
  • 4D pharma plc
*We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

*Please Note:* The report will take 7 business days to complete, after order confirmation.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Human Microbiome Market Overview
3.1 Global Human Microbiome Market Historical Value (2016-2022)
3.2 Global Human Microbiome Market Forecast Value (2023-2031)
4 Global Human Microbiome Market Dynamics
4.1 Market Drivers and Constraints
4.2 SWOT Analysis
4.3 Porter’s Five Forces Model
4.4 Key Demand Indicators
4.5 Key Price Indicators
4.6 Industry Events, Initiatives, and Trends
4.7 Value Chain Analysis
5 Global Human Microbiome Market Segmentation
5.1 Global Human Microbiome Market by Product Type
5.1.1 Market Overview
5.1.2 Probiotics
5.1.3 Prebiotics
5.1.4 Medical Foods
5.1.5 Supplements
5.1.6 Others
5.2 Global Human Microbiome Market by Application
5.2.1 Market Overview
5.2.2 Therapeutics
5.2.3 Diagnostics
5.3 Global Human Microbiome Market by Disease Type
5.3.1 Market Overview
5.3.2 Obesity
5.3.3 Diabetes
5.3.4 Autoimmune Disorder
5.3.5 Metabolic and Gastrointestinal Disorders
5.3.6 Cancer
5.3.7 Other Disease
5.4 Global Human Microbiome Market by Distribution Channel
5.4.1 Market Overview
5.4.2 Retail Pharmacies
5.4.3 Online Pharmacies
5.4.4 Supermarkets and Hypermarkets
5.4.5 Others
5.5 Global Human Microbiome Market by Region
5.5.1 Market Overview
5.5.2 North America
5.5.3 Europe
5.5.4 Asia Pacific
5.5.5 Latin America
5.5.6 Middle East and Africa
6 North America Human Microbiome Market
6.1 Market Share by Country
6.2 United States of America
6.3 Canada
7 Europe Human Microbiome Market
7.1 Market Share by Country
7.2 United Kingdom
7.3 Germany
7.4 France
7.5 Italy
7.6 Others
8 Asia Pacific Human Microbiome Market
8.1 Market Share by Country
8.2 China
8.3 Japan
8.4 India
8.5 ASEAN
8.6 Australia
8.7 Others
9 Latin America Human Microbiome Market
9.1 Market Share by Country
9.2 Brazil
9.3 Argentina
9.4 Mexico
9.5 Others
10 Middle East and Africa Human Microbiome Market
10.1 Market Share by Country
10.2 Saudi Arabia
10.3 United Arab Emirates
10.4 Nigeria
10.5 South Africa
10.6 Others
11 Patent Analysis
11.1 Analysis by Type of Patent
11.2 Analysis by Publication year
11.3 Analysis by Issuing Authority
11.4 Analysis by Patent Age
11.5 Analysis by CPC Analysis
11.6 Analysis by Patent Valuation
11.7 Analysis by Key Players
12 Grants Analysis
12.1 Analysis by year
12.2 Analysis by Amount Awarded
12.3 Analysis by Issuing Authority
12.4 Analysis by Grant Application
12.5 Analysis by Funding Institute
12.6 Analysis by NIH Departments
12.7 Analysis by Recipient Organization
13 Funding Analysis
13.1 Analysis by Funding Instances
13.2 Analysis by Type of Funding
13.3 Analysis by Funding Amount
13.4 Analysis by Leading Players
13.5 Analysis by Leading Investors
13.6 Analysis by Geography
14 Partnership and Collaborations Analysis
14.1 Analysis by Partnership Instances
14.2 Analysis by Type of Partnership
14.3 Analysis by Leading Players
14.4 Analysis by Geography
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 INDIA CDSCO
15.1.4 JAPAN PMDA
15.1.5 Others
16 Supplier Landscape
16.1 ENTEROME
16.1.1 Financial Analysis
16.1.2 Product Portfolio
16.1.3 Demographic Reach and Achievements
16.1.4 Mergers and Acquisitions
16.1.5 Certifications
16.2 Yakult
16.2.1 Financial Analysis
16.2.2 Product Portfolio
16.2.3 Demographic Reach and Achievements
16.2.4 Mergers and Acquisitions
16.2.5 Certifications
16.3 DuPont
16.3.1 Financial Analysis
16.3.2 Product Portfolio
16.3.3 Demographic Reach and Achievements
16.3.4 Mergers and Acquisitions
16.3.5 Certifications
16.4 Metabiomics Corporation
16.4.1 Financial Analysis
16.4.2 Financial Portfolio
16.4.3 Demographic Reach and Achievements
16.4.4 Mergers and Acquisitions
16.4.5 Certifications
16.5 ViThera Pharmaceuticals, Inc.
16.5.1 Financial Analysis
16.5.2 Product Portfolio
16.5.3 Demographic Reach and Achievements
16.5.4 Mergers and Acquisitions
16.5.5 Certifications
16.6 Second Genome Inc.
16.6.1 Financial Analysis
16.6.2 Product Portfolio
16.6.3 Demographic Reach and Achievements
16.6.4 Mergers and Acquisitions
16.6.5 Certifications
16.7 MICROBIOME THERAPEUTICS LLC
16.7.1 Financial Analysis
16.7.2 Product Portfolio
16.7.3 Demographic Reach and Achievements
16.7.4 Mergers and Acquisitions
16.7.5 Certifications
16.8 Vedanta Biosciences, Inc.
16.8.1 Financial Analysis
16.8.2 Product Portfolio
16.8.3 Demographic Reach and Achievements
16.8.4 Mergers and Acquisitions
16.8.5 Certifications
16.9 Osel, Inc.
16.9.1 Financial Analysis
16.9.2 Product Portfolio
16.9.3 Demographic Reach and Achievements
16.9.4 Mergers and Acquisitions
16.9.5 Certifications
16.10 Merck Sharp & Dohme Corp
16.10.1 Financial Analysis
16.10.2 Product Portfolio
16.10.3 Demographic Reach and Achievements
16.10.4 Mergers and Acquisitions
16.10.5 Certifications
16.11 Seres Therapeutics
16.11.1 Financial Analysis
16.11.2 Product Portfolio
16.11.3 Demographic Reach and Achievements
16.11.4 Mergers and Acquisitions
16.11.5 Certifications
16.12 Synthetic Biologics, Inc.
16.12.1 Financial Analysis
16.12.2 Product Portfolio
16.12.3 Demographic Reach and Achievements
16.12.4 Mergers and Acquisitions
16.12.5 Certifications
16.13 4D pharma plc
16.13.1 Financial Analysis
16.13.2 Product Portfolio
16.13.3 Demographic Reach and Achievements
16.13.4 Mergers and Acquisitions
16.13.5 Certifications
17 Global Human Microbiome Market - Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings